Our Products News
-
Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic DiseaseRibo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic DiseaseMay 28, 2026 -
Ribo Advances Clinical Development of FXI siRNA vortosiran with EMA Phase 2b CTA Submission in Venous Thromboembolism, ORBIT-FXI-VTERibo has submitted a Phase 2b CTA to the EMA for vortosiran (RBD4059) to prevent venous thromboembolism.May 11, 2026 -
Ribo Submits Phase 2b Clinical Trial Application for world’s first siRNA FXI inhibitor in atrial fibrillationRibo Submits Phase 2b Clinical Trial Application for world’s first siRNA FXI inhibitor in atrial fibrillationApril 14, 2026 -
Ribo expands beyond the liver with RiboPepSTAR? – enabling targeted siRNA delivery to multiple organsRibo expands beyond the liver with RiboPepSTAR? – enabling targeted siRNA delivery to multiple organsMarch 20, 2026 -
Ribo to present ex-hepatic delivery data at RNA Leaders Europe ConferenceRibo has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleotide conferences.March 17, 2026 -
Ribo's PCSK9-targeting siRNA drug RBD7022 is about to launch Phase III clinical trials in China.Ribo's PCSK9-targeting siRNA drug RBD7022 is about to launch Phase III clinical trials in China.March 2, 2026